Biogenysis, a subsidiary of Enzolytics, Inc., has announced a continued partnership with Khalpey AI Lab and Contenta, Ltd. to identify biomarkers for early onset Alzheimer’s disease. The collaboration aims to discover biomarkers that can enable early diagnosis and the development of preventative therapies to slow down the progression of the disease.
Alzheimer’s disease affects millions of people in the United States and has a significant economic impact, with the cost of care reaching billions of dollars each year. Unfortunately, the number of cases is expected to double by 2050, resulting in an even greater economic burden. Despite the growing prevalence of the disease, diagnosis and treatment rates remain low at all stages.
To address this challenge, Biogenysis, Khalpey AI Lab, and Contenta, Ltd. are harnessing the power of artificial intelligence (AI) to analyze biomarkers associated with Alzheimer’s disease. AI has shown promise in various fields, and its application in identifying and validating biomarkers could revolutionize the early detection and treatment of Alzheimer’s. By analyzing the gut microbiota of thousands of patients, the collaboration aims to identify those at higher risk of developing dementia and design preventative treatments.
The CEO of Contenta, Ltd., Riin Ehin, expressed their excitement to be part of the consortium and make a positive impact on Alzheimer’s disease patients. Estonia, known for its focus on gut microbiota in immunity, brings valuable expertise to the partnership. Dr. Kirsten Bischof, an AI Advisory Board Member at Biogenysis, highlighted the immense potential of AI in analyzing gut-brain communication and identifying new biomarkers for neurodegenerative illnesses.
Dr. Zain Khalpey, the Director of the Khalpey AI Lab, emphasized the commitment to advancing AI in healthcare and the significant step forward in the fight against Alzheimer’s disease through this partnership. Dr. Gaurav Chandra, CEO of Biogenysis, highlighted the need to find early biomarkers for Alzheimer’s and discover new therapeutic targets to slow down its progression.
Enzolytics, Inc., the parent company of Biogenysis, is dedicated to commercializing its proprietary monoclonal antibodies and proteins to treat infectious diseases. Enzolytics utilizes its AI platform to develop effective therapies, and this partnership with Khalpey AI Lab and Contenta, Ltd. aligns with their objective of using AI to improve healthcare outcomes.
The CEO of Enzolytics, Charles Cotropia, emphasized the transformative potential of AI in various areas, including healthcare. He cited the four pending international patent applications filed by the company, claiming significant discoveries derived from their AI platform. The collaboration and Enzolytics’ planned business combination with Sagaliam Acquisition Corporation will further accelerate their goal of using AI to develop infectious disease therapeutics.
In conclusion, Biogenysis, in partnership with Khalpey AI Lab and Contenta, Ltd., is leveraging AI to identify biomarkers for early onset Alzheimer’s disease. This collaboration holds promise for early diagnosis and the design of preventative therapies to slow down the progression of the disease. With the commitment to advancing AI in healthcare, the partnership aims to make a significant impact in the fight against Alzheimer’s.
